Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16ClN3O |
Molecular Weight | 313.781 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(OC3=C(C=CC=C3)N=C2N4CCNCC4)C=C1
InChI
InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
Molecular Formula | C17H16ClN3O |
Molecular Weight | 313.781 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096905 |
|||
Target ID: CHEMBL222 |
|||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15655900 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AMOXAPINE Approved UseAmoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. Launch Date1992 |
|||
Primary | AMOXAPINE Approved UseAmoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. Launch Date1992 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.55 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
319 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.02 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Drowsiness, Dry mouth... Other AEs: Drowsiness (14%) Sources: Dry mouth (14%) Constipation (12%) Blurred vision (7%) Anxiety (>1) Insomnia (>1) Nervousness (>1) Nightmare (>1) Restlessness (>1) Palpitations (>1) Tremor (>1) Confusion (>1) Excitement (>1) Ataxia (>1) Edema (>1) Skin rash (>1) Prolactin increased (>1) Nausea (>1) Dizziness (>1) Headache (>1) Fatigue (>1) Weakness (>1) Appetite excessive (>1) Perspiration excessive (>1) Accommodation disturbance (<1%) Mydriasis (<1%) Micturition disorder (<1%) Urinary retention (<1%) Nasal stuffiness (<1%) Hypotension (<1%) Hypertension (<1%) Syncope (<1%) Tachycardia (<1%) Drug fever (<1%) Urticaria (<1%) Photosensitized (<1%) Pruritus (<1%) Vasculitis (<1%) Hepatitis (<1%) Tingling (<1%) Tinnitus (<1%) Disorientation (<1%) Seizures (<1%) Hypomania (<1%) Numbness (<1%) Incoordination (<1%) Concentration impairment (<1%) Hyperthermia (<1%) Extrapyramidal symptoms (<1%) Tardive dyskinesia (<1%) Leukopenia (<1%) Agranulocytosis (<1%) Epigastric distress (<1%) Vomiting (<1%) Flatulence (<1%) Abdominal pain (<1%) Taste peculiar (<1%) Diarrhea (<1%) Impotence (<1%) Menstrual irregularity (<1%) Breast enlargement (<1%) Inappropriate antidiuretic hormone secretion (<1%) Galactorrhea (<1%) Lacrimation (<1%) Weight gain (<1%) Weight loss (<1%) Impaired liver function (<1%) Painful ejaculation (<1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Constipation | 12% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Drowsiness | 14% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dry mouth | 14% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Blurred vision | 7% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Abdominal pain | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Accommodation disturbance | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Agranulocytosis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Breast enlargement | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Concentration impairment | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disorientation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Drug fever | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Epigastric distress | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Extrapyramidal symptoms | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Flatulence | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Galactorrhea | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hepatitis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypertension | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hyperthermia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypomania | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypotension | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Impaired liver function | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Impotence | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Inappropriate antidiuretic hormone secretion | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Incoordination | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Lacrimation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Leukopenia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Menstrual irregularity | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Micturition disorder | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Mydriasis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Nasal stuffiness | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Numbness | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Painful ejaculation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Photosensitized | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Pruritus | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Seizures | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Syncope | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Tachycardia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Tardive dyskinesia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Taste peculiar | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Tingling | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Tinnitus | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Urinary retention | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Urticaria | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Vasculitis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Vomiting | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Weight gain | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Weight loss | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Anxiety | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Appetite excessive | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Ataxia | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Confusion | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Dizziness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Edema | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Excitement | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Fatigue | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Headache | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Insomnia | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Nausea | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Nervousness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Nightmare | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Palpitations | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Perspiration excessive | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Prolactin increased | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Restlessness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Skin rash | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Tremor | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Weakness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Amoxapine-associated acute renal failure. | 1985 Jun |
|
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. | 1985 Oct |
|
Serum neuroleptic levels and extrapyramidal side effects in patients treated with amoxapine. | 1985 Oct |
|
Amoxapine-induced extrapyramidal effects. | 1986 Jun |
|
Amoxapine-induced cognitive impairment in two patients. | 1987 Apr |
|
Acute myocardial failure following amoxapine intoxication. | 1988 Feb |
|
Biochemical evidence that high concentrations of the antidepressant amoxapine may cause inhibition of mitochondrial electron transport. | 1988 Mar 30 |
|
Depressive disorders preceding temporal lobe epilepsy. | 2002 Apr |
|
Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. | 2002 Aug |
|
[Case of prolonged recovery from serotonin syndrome caused by paroxetine]. | 2003 |
|
Biological pathophysiology of mood disorders special reference to the neurotransmitter receptors. | 2004 |
|
Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. | 2004 |
|
Amoxapine in schizophrenia: a negative double-blind controlled trial. | 2004 Aug |
|
Photo-distributed neutrophilic drug eruption and adult respiratory distress syndrome associated with antidepressant therapy. | 2004 Feb |
|
Pharmacological properties of glycine transport in the frog retina. | 2004 Jan |
|
Possible serotonin syndrome arising from an interaction between caffeine and serotonergic antidepressants. | 2004 Jul |
|
Intrathecal tri-cyclic antidepressants produce spinal anesthesia. | 2004 Nov |
|
Risk of fetal exposure to tricyclic antidepressants. | 2004 Oct |
|
The pharmacological management of depression. | 2005 |
|
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. | 2005 Dec |
|
Facilitation of spontaneous glutamate release by antidepressant drugs in rat locus coeruleus. | 2005 Feb 10 |
|
Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report. | 2005 Jul-Aug |
|
[Treatment for irritable bowel syndrome--psychotropic drugs, antidepressants and so on]. | 2006 Aug |
|
A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. | 2006 Feb |
|
Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection. | 2006 Feb |
|
Risperidone in the treatment of psychotic depression. | 2006 Jun |
|
[Case of amoxapine-induced refractory status epilepticus which was successfully treated with propofol]. | 2006 Oct |
|
Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature. | 2007 Dec |
|
Amoxapine as an antipsychotic: comparative study versus haloperidol. | 2007 Dec |
|
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. | 2007 Jul 26 |
|
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs. | 2007 Mar |
|
Differential distribution of glycine transporters in Müller cells and neurons in amphibian retinas. | 2007 Mar-Apr |
|
Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood. | 2007 May |
|
Pharmacological causes of hyperprolactinemia. | 2007 Oct |
|
Prevalence and predictors of antidepressant use in a cohort of pregnant women. | 2007 Sep |
|
Effects of different antidepressant treatments on the core of depression. | 2008 |
|
An autopsy case of poisoning with ethanol and psychotropic drugs. | 2008 Apr |
|
Amoxapine-associated acute respiratory distress. | 2008 Jan |
|
Determination of tricyclic antidepressants in human plasma using pipette tip solid-phase extraction and gas chromatography-mass spectrometry. | 2008 Jul |
|
Functional expression of the glycine transporter 1 on bullfrog retinal cones. | 2008 Nov 19 |
|
Effectiveness of a multifactorial cardiovascular risk reduction clinic for diabetes patients with depression. | 2008 Oct |
|
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | 2009 Dec 2 |
|
A new strategy for antidepressant prescription. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways. | 2010 Feb |
|
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010 Feb 23 |
|
Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect. | 2010 Jan |
|
Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. | 2010 Mar |
|
Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. | 2010 May |
|
Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray. | 2010 Nov 30 |
Sample Use Guides
Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19915071
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:28:48 GMT 2025
by
admin
on
Mon Mar 31 19:28:48 GMT 2025
|
Record UNII |
R63VQ857OT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06AA17
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
||
|
NDF-RT |
N0000175752
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
||
|
WHO-ATC |
N06AA17
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
||
|
LIVERTOX |
NBK548520
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
||
|
NCI_THESAURUS |
C94727
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
191
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
SUB05479MIG
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
Amoxapine
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
722
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
R63VQ857OT
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
14028-44-5
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
1031401
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
201
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
m1843
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
2675
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
237-867-1
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
3049
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
DB00543
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
759559
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
DTXSID7022598
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
Amoxapine
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
R63VQ857OT
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
2170
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
D000657
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL1113
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
100000087430
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY | |||
|
C47397
Created by
admin on Mon Mar 31 19:28:48 GMT 2025 , Edited by admin on Mon Mar 31 19:28:48 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||